Biocorp and Novo Mallya Partnership; Nemaura Signs Contract for Non-invasive CGM EU Distribution; AHA Late-breaking Science Sessions Released; EASD 2021 Key Press Releases (Sept 27)
On the first day of EASD 2021, two key press releases were observed from Biocorp and Nemaura Medical. Additionally, AHA late-breaking science sessions have been released. Below FENIX provides insights and context from each respective announcement, including thoughts on how the Biocorp/Novo Nordisk partnership could signal Novo’s disposable connected pen solution is further behind than previously anticipated.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.